New combo therapy aims to stop liver Cancer's return in High-Risk patients
NCT ID NCT06644937
First seen Oct 01, 2025 · Last updated May 05, 2026 · Updated 27 times
Summary
This study tests whether a treatment called TACE combined with the drug icaritin can help prevent liver cancer from returning after surgery in patients at high risk of recurrence. About 30 adults with hepatocellular carcinoma who had complete tumor removal will receive the combination therapy. The main goal is to see how many patients remain cancer-free one year after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhujiang Hospital, Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.